Skip to main content

Advertisement

SpringerLink
Log in

B Cell Lymphomas of the GI Tract

  • Small Intestine (A Stein, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

Primary GI lymphomas of B cell origin are a diverse group of lymphomas. In this article, we provide an overview of the diagnosis, pathologic and molecular features, and management of these varied lymphomas.

Recent Findings

The most common primary GI lymphomas are diffuse large B cell lymphoma (DLBCL) and marginal zone lymphomas (MZL), but follicular lymphomas (FL), mantle cell lymphomas (MCL), post-transplant lymphoproliferative disorders (PTLD), and Burkitt lymphoma of the GI tract also occur. Many features of these lymphomas are similar to their nodal counterparts, but certain clinical and biological aspects are unique. Diagnostic and treatment strategies for these lymphomas continue to evolve over time.

Summary

There are ongoing discoveries about the unique pathophysiology, molecular characteristics, and complications of primary B cell GI lymphomas that are already leading to improvements in management of this histologically diverse set of lymphomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969–2017). National Cancer Institute, DCCPS, Surveillance Research Program, released December 2019 Underlying mortality data provided by NCHS (wwwcdcgov/nchs).

  2. Bautista-Quach MA, Ake CD, Chen M, Wang J. Gastrointestinal lymphomas: morphology, immunophenotype and molecular features. J Gastrointest Oncol. 2012;3(3):209–25.

    PubMed  PubMed Central  Google Scholar 

  3. Shuji Yamamoto HN, Yamashita K, Matsuura M, Takada M, Kawanami C, Chiba T. Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol. 2010;45:370–88.

    Article  Google Scholar 

  4. Takata K, Miyata-Takata T, Sato Y, Iwamuro M, Okada H, Tari A, et al. Gastrointestinal follicular lymphoma: current knowledge and future challenges. Pathol Int. 2018;68(1):1–6 Review that differentiates between nodal FL and GI-FL.

    Article  Google Scholar 

  5. Takata K, Tanino M, Ennishi D, Tari A, Sato Y, Okada H, et al. Duodenal follicular lymphoma: comprehensive gene expression analysis with insights into pathogenesis. Cancer Sci. 2014;105(5):608–15.

  6. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. 4 ed2017.

  7. Marks E, Shi Y. Duodenal-type follicular lymphoma: a Clinicopathologic review. Arch Pathol Lab Med. 2018;142(4):542–7.

    Article  CAS  Google Scholar 

  8. Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127(17):2055–63.

    Article  CAS  Google Scholar 

  9. Zelenetz AD, Chu G, Galili N, Bangs CD, Horning SJ, Donlon TA, et al. Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. Blood. 1991;78(6):1552–60.

  10. Launay E, Pangault C, Bertrand P, Jardin F, Lamy T, Tilly H, et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia. 2012;26(3):559–62.

  11. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298–303.

  12. Mamessier E, Song JY, Eberle FC, Pack S, Drevet C, Chetaille B, et al. Early lesions of follicular lymphoma: a genetic perspective. Haematologica. 2014;99(3):481–8.

  13. Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. New England Journal of Medicine. 2018;379(10):934–47 Clinical Trial with comparison of ritxuimab + chemotherapy to rituximab + lenalidomide in previously-untreated follicular lymphoma.

    Article  CAS  Google Scholar 

  14. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.

  15. Olszewska-Szopa M, Wróbel T. Gastrointestinal non-Hodgkin lymphomas. Adv Clin Exp Med. 2019;28(8):1119–24.

    Article  Google Scholar 

  16. Eck M, Schmausser B, Haas R, Greiner A, Czub S, Müller-Hermelink HK. MALT-type lymphoma of the stomach is associated with helicobacter pylori strains expressing the CagA protein. Gastroenterology. 1997;112(5):1482–6.

    Article  CAS  Google Scholar 

  17. Lin W-C, Tsai H-F, Kuo S-H, Wu M-S, Lin C-W, Hsu P-I, et al. Translocation of helicobacter pylori CagA into human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res. 2010;70(14):5740–8.

  18. Thieblemont C, Zucca E. Clinical aspects and therapy of gastrointestinal MALT lymphoma. Best Pract Res Clin Haematol. 2017;30(1–2):109–17.

    Article  Google Scholar 

  19. Zucca E, Bertoni F, Vannata B, Cavalli F. Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. Clin Cancer Res. 2014;20(20):5207–16.

    Article  CAS  Google Scholar 

  20. Ghimire P, Wu G-Y, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17(6):697–707.

    Article  Google Scholar 

  21. Vetro C, Romano A, Amico I, Conticello C, Motta G, Figuera A, et al. Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up. World J Gastroenterol. 2014;20(36):12993–3005.

  22. Isaacson PG, Wotherspoon AC, Diss T, Pan LX. Follicular colonization in B-cell lymphoma of mucosa-associated lymphoid tissue. Am J Surg Pathol. 1991;15(9):819–28.

    Article  CAS  Google Scholar 

  23. Jaffe E, Arber DA, Campo E, Harris NL, Jaffe ES, Quintanilla-Martinez L. Hematopathology. 2nd ed. Philadelphia: PA Elsevier; 2017.

    Google Scholar 

  24. Liu H, Ye H. Ruskone–Fourmestraux a, De Jong D, Pileri S, Thiede C, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology. 2002;122(5):1286–94.

    Article  CAS  Google Scholar 

  25. Du M-Q. MALT lymphoma: genetic abnormalities, immunological stimulation and molecular mechanism. Best Pract Res Clin Haematol. 2017;30(1):13–23.

    Article  Google Scholar 

  26. Wang Z, Cook JR. IRTA1 and MNDA expression in marginal zone lymphoma: utility in differential diagnosis and implications for classification. Am J Clin Pathol. 2019;151(3):337–43.

    Article  CAS  Google Scholar 

  27. Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116(16):3815–24.

  28. Martinelli G, Laszlo D, Ferreri AJM, Pruneri G, Ponzoni M, Conconi A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti–helicobacter pylori therapy. J Clin Oncol. 2005;23(9):1979–83.

  29. Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–32 Phase 2 study that evaluates the BTK inhibitor ibrutinib in previously-treated MZL.

    Article  CAS  Google Scholar 

  30. Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer. 2018;8:63–70.

    Article  CAS  Google Scholar 

  31. Choi SY, Kim SJ, Kim WS, Kim K, Ko YH. Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis. Virchows Arch. 2011;459(5):495–502.

    Article  CAS  Google Scholar 

  32. Xia B, Zhang L, Guo S-Q, Li X-W, Qu F-L, Zhao H-F, et al. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma. World J Gastroenterol. 2015;21(8):2433–42.

  33. Liu Y, Yu K, Li M, Zeng K, Wei J, Li X, et al. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features. Hum Pathol. 2017;64:213–21.

  34. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.

  35. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL rituximab-CHOP consortium program. Blood. 2013;121(20):4021–31.

  36. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.

  37. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–407.

  38. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–90.

  39. Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological malignancy research network report. Blood. 2020;135(20):1759–71.

  40. Zelentz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Budde LE, et al. NCCN clinical practice guidelines in oncology: B-cell lymphomas. Version 4.2020. Available at: NCCNorg.

  41. Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609-e17. Phase 2 study that supports DA-EPOCH-R use in MYC-rearranged DLBCL.

  42. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(28):3452–9.

  43. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533–7.

  44. Hanafy AK, Morani AC, Menias CO, Pickhardt PJ, Shaaban AM, Mujtaba B, et al. Hematologic malignancies of the gastrointestinal luminal tract. Abdom Radiol (NY). 2019. Review article that includes common and rare hematologic malignancies of the GI tract, including radiological imaging of the malignancies.

  45. Ruskoné-Fourmestraux A, Audouin J. Primary gastrointestinal tract mantle cell lymphoma as multiple lymphomatous polyposis. Best Pract Res Clin Gastroenterol. 2010;24(1):35–42.

    Article  Google Scholar 

  46. Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer Journal. 2019;9(6):50.

  47. Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, et al. 15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410–8.

  48. Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med. 2017;377(13):1250–60 Phase 3 clinical trial that shows imporved overall survival in MCL patients with rituximab maintenance therapy (compared to placebo) after auto transplant.

    Article  Google Scholar 

  49. Schieber M, Gordon LI, Karmali R. Current overview and treatment of mantle cell lymphoma. F1000Res. 2018;7.

  50. Jeong TD, Chi HS, Kim MS, Jang S, Park CJ, Huh JR. Prognostic relevance of the Ki-67 proliferation index in patients with mantle cell lymphoma. Blood Res. 2016;51(2):127–32.

    Article  CAS  Google Scholar 

  51. Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, et al. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. J Clin Oncol. 2017;35(5):536–43 Phase 2 clinical trial that established rituximab +/− escalation to R-CHOP as treatment for PTLD, and showed that rsponse to rituximab is a prognostic factor for overall survival.

    Article  CAS  Google Scholar 

  52. Dierickx D, Habermann TM. Post-transplantation Lymphoproliferative disorders in adults. N Engl J Med. 2018;378(6):549–62.

    Article  CAS  Google Scholar 

  53. Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94(7):2208–16.

    CAS  PubMed  Google Scholar 

  54. Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS guidelines. Br J Haematol. 2010;149(5):693–705.

  55. Swinnen LJ, LeBlanc M, Grogan TM, Gordon LI, Stiff PJ, Miller AM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 2008;86(2):215–22.

  56. Dawson I, Cornes J, Morson B. Primary malignant lymphoid tumors of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg. 1961;49:80–9.

    Article  CAS  Google Scholar 

  57. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.

  58. Ibuka T, Araki H, Sugiyama T, Nakanishi T, Onogi F, Shimizu M, et al. Diagnosis of the jejunoileal lymphoma by double-balloon endoscopy. World J Gastrointest Endosc. 2013;5(3):111–6.

  59. Cornejo A, Bohnenblus M, Harris C, Abrahamian G. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation. Cancer chemotherapy and pharmacology. 2009;64(4).

  60. Moudi M, Go R, Yien CYS, Nazre M. Vinca alkaloids. Int J Prev Med. 2013;4(11):1231–5.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Northwestern University, Chicago, IL, USA

    Sara Small & Reem Karmali

  2. Division of Pathology, Northwestern University, Chicago, IL, USA

    Liron Barnea Slonim

  3. Robert H. Lurie Comprehensive Cancer Center, 675 N. St. Clair St.Fl 21 Ste. 100, Chicago, IL, 60611, USA

    Corinne Williams & Reem Karmali

Authors
  1. Sara Small
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liron Barnea Slonim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Corinne Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reem Karmali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Reem Karmali.

Ethics declarations

Conflict of Interest

Reem Karmali reports grants and personal fees from Gilead/Kite, grants and personal fees from BMS/Celgene/Juno, grants from Takeda, personal fees from BeiGene, personal fees from AstraZeneca, personal fees from Karyopharm, outside the submitted work.

Corinne Williams reports personal fees from AstraZeneca, personal fees from Janssen, outside the submitted work.

Sara Small and Liron Barnea Slonim declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Small Intestine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Small, S., Barnea Slonim, L., Williams, C. et al. B Cell Lymphomas of the GI Tract. Curr Gastroenterol Rep 23, 9 (2021). https://doi.org/10.1007/s11894-021-00811-8

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11894-021-00811-8

Keywords

Search

Navigation